Global pharmaceutical manufacturer Bora Pharmaceuticals has renewed its manufacturing agreement with GlaxoSmithKline (GSK), signing a new contract worth $250 million to extend the partnership for five years. This agreement strengthens the collaboration between the two parties in the field of pharmaceutical manufacturing, enabling GSK to utilize multiple production sites within Bora's network, including an oral solid dosage facility located in Minnesota. The manufacturing agreement between Bora and GSK ensures the continued global availability of critical therapies for patients.
GSK is Bora's largest partner at the Mississauga facility, which manages the production processes for over 225 different products. Bora acquired the facility from GSK in 2020 and continues to provide comprehensive manufacturing services for more than 20 commercial product lines. Drugs produced at the facility cover a range of diseases, such as HIV, malaria, pneumonia, depression, and migraines, as well as dermatological treatments for acne, eczema, and psoriasis. By renewing the contract, GSK will continue to rely on Bora's manufacturing capabilities to ensure a stable supply of these essential medicines.
J.D. Mowery, President of Bora's CDMO division, stated, "Strong partnerships like this are the foundation of the continued growth of Bora's CDMO business. GSK's ongoing trust in Bora demonstrates our robust execution capabilities in development and commercial manufacturing and supports our trend of expanding influence as a preferred global CDMO." Since its integration into the Bora network, the Mississauga facility has enhanced its technical capabilities and expanded its client base.
The company attributes its growth to targeted investments in flexible manufacturing technologies. These investments have enabled the facility to serve 32 clients, advance 61 products, and complete over 400 project and development batches. John Lawrie, Vice President of Operations at Bora's Mississauga site, said, "Ultimately, partnerships are realized on the manufacturing floor. Our team, systems, and processes are prepared to consistently deliver on time and in full, supporting the production of GSK's medicines." Bobby Sheng, Chairman and CEO of the Bora Group, added, "Working with GSK for nearly a decade and committing to cooperate until 2030 reflects our shared emphasis on value and reliability. We are grateful for the opportunity to continue supporting GSK's goals and the patients who depend on these therapies." This manufacturing agreement between Bora and GSK further solidifies their long-term partnership in the pharmaceutical industry.
